One number in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
← favours treatmentfavours comparator →
could be chanceCardiovascular events
−85.0−92.7 to −77.3
StatinsPCSK9 inhibitorsCardiovascular events
1 / 3
TrialDiabetes, obesity & metabolism2019
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.
Yundai Chen et al.PubMed ↗Full text ↗Publisher ↗
What the trial testedrandomised · 453 people · 2019
Randomised comparison
Probably reduced cardiovascular events
−85.0percentage points−92.7 to −77.3
As reported
difference −85.0 %, 95% CI −92.7 to −77.3
22 papers cite it
this paperpooled ittrialcites it